Drugs / DSP-1349M
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03627195 | Jun 2018 → Mar 2019 | schizophrenia | Sumitomo Pharma America, Inc. | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DSP-1349M | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03627195 ↗ |